BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 33331946)

  • 1. Difficult-to-treat rheumatoid arthritis: contributing factors and burden of disease.
    Roodenrijs NMT; van der Goes MC; Welsing PMJ; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
    Rheumatology (Oxford); 2021 Aug; 60(8):3778-3788. PubMed ID: 33331946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Review of Difficult-to-Treat Rheumatoid Arthritis: Definition, Clinical Presentation, and Management.
    Conran C; Kolfenbach J; Kuhn K; Striebich C; Moreland L
    Curr Rheumatol Rep; 2023 Dec; 25(12):285-294. PubMed ID: 37776482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare utilization and economic burden of difficult-to-treat rheumatoid arthritis: a cost-of-illness study.
    Roodenrijs NMT; Welsing PMJ; van der Goes MC; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM
    Rheumatology (Oxford); 2021 Oct; 60(10):4681-4690. PubMed ID: 33502493
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and insights in managing difficult-to-treat rheumatoid arthritis: real-world clinical perspectives.
    Alp G; Cinakli H; Kurut Aysin İ; Solmaz D; Akar S
    Clin Exp Rheumatol; 2024 Jan; ():. PubMed ID: 38372714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease.
    Leon L; Madrid-Garcia A; Lopez-Viejo P; González-Álvaro I; Novella-Navarro M; Freites Nuñez D; Rosales Z; Fernandez-Gutierrez B; Abasolo L
    RMD Open; 2023 Mar; 9(1):. PubMed ID: 36889800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Difficult to treat' rheumatoid arthritis: current position and considerations for next steps.
    Tan Y; Buch MH
    RMD Open; 2022 Jul; 8(2):. PubMed ID: 35896282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-adherence in difficult-to-treat rheumatoid arthritis from the perspectives of patients and rheumatologists: a concept mapping study.
    Roodenrijs NMT; van der Goes MC; Welsing PMJ; van Oorschot EPC; Nikiphorou E; Nijhof NC; Tekstra J; Lafeber FPJG; Jacobs JWG; van Laar JM; Geenen R
    Rheumatology (Oxford); 2021 Nov; 60(11):5105-5116. PubMed ID: 33560301
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study.
    Giollo A; Zen M; Larosa M; Astorri D; Salvato M; Calligaro A; Botsios K; Bernardi C; Bianchi G; Doria A
    Rheumatology (Oxford); 2023 Jun; 62(6):2083-2089. PubMed ID: 36190344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly-Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes.
    David P; Di Matteo A; Hen O; Dass S; Marzo-Ortega H; Wakefield RJ; Bissell LA; Nam J; Mankia K; Emery P; Saleem B; McGonagle D
    Arthritis Rheumatol; 2024 Apr; 76(4):510-521. PubMed ID: 38059326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry.
    Ochi S; Sonomoto K; Nakayamada S; Tanaka Y
    Arthritis Res Ther; 2022 Mar; 24(1):61. PubMed ID: 35232462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics Of Difficult-To-Treat Psoriatic Arthritis: A Comparative Analysis.
    Philippoteaux C; Marty-Ane A; Cailliau E; Labreuche J; Philippe P; Cortet B; Paccou J; Flipo RM; Letarouilly JG
    Semin Arthritis Rheum; 2023 Dec; 63():152275. PubMed ID: 37852155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice.
    Takanashi S; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2021 Nov; 60(11):5247-5256. PubMed ID: 33682890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and predictive factors of difficult-to-treat rheumatoid arthritis: the KURAMA cohort.
    Watanabe R; Hashimoto M; Murata K; Murakami K; Tanaka M; Ohmura K; Ito H; Matsuda S
    Immunol Med; 2022 Mar; 45(1):35-44. PubMed ID: 34033729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Difficult to treat rheumatoid arthritis in a comprehensive evaluation program: frequency according to different objective evaluations.
    Garcia-Salinas R; Sanchez-Prado E; Mareco J; Ronald P; Ruta S; Gomez R; Magri S
    Rheumatol Int; 2023 Oct; 43(10):1821-1828. PubMed ID: 37269430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis.
    Bertsias A; Flouri ID; Repa A; Avgoustidis N; Kalogiannaki E; Pitsigavdaki S; Bertsias G; Sidiropoulos P
    RMD Open; 2024 Jan; 10(1):. PubMed ID: 38242549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Difficult-to-treat rheumatoid arthritis in real clinical practice. Preliminary results].
    Galushko EA; Gordeev AV; Matyanova EV; Olyunin YA; Nasonov EL
    Ter Arkh; 2022 Jun; 94(5):661-666. PubMed ID: 36286966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and ultrasound features of difficult-to-treat rheumatoid arthritis: A multicenter RA ultrasound cohort study.
    Michitsuji T; Fukui S; Morimoto S; Endo Y; Nishino A; Nishihata S; Tsuji Y; Shimizu T; Umeda M; Sumiyoshi R; Koga T; Iwamoto N; Origuchi T; Ueki Y; Yoshitama T; Eiraku N; Matsuoka N; Okada A; Fujikawa K; Ohtsubo H; Takaoka H; Hamada H; Tsuru T; Nawata M; Arinobu Y; Hidaka T; Tada Y; Kawakami A; Kawashiri SY
    Scand J Rheumatol; 2024 Mar; 53(2):123-129. PubMed ID: 38085537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inappropriate treatment response to DMARDs: A pathway to difficult-to-treat rheumatoid arthritis.
    Guo H; Li L; Liu B; Lu P; Cao Z; Ji X; Li L; Ouyang G; Nie Z; Lyu A; Lu C
    Int Immunopharmacol; 2023 Sep; 122():110655. PubMed ID: 37481847
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unveiling difficult-to-treat rheumatoid arthritis: long-term impact of biologic or targeted synthetic DMARDs from the KOBIO registry.
    Jung JY; Lee E; Kim JW; Suh CH; Shin K; Kim J; Kim HA
    Arthritis Res Ther; 2023 Sep; 25(1):174. PubMed ID: 37726808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic issues in difficult-to-treat rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of difficult-to-treat rheumatoid arthritis.
    Roodenrijs NMT; Kedves M; Hamar A; Nagy G; van Laar JM; van der Heijde D; Welsing PMJ
    RMD Open; 2021 Jan; 7(1):. PubMed ID: 33514671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.